RecruitingNCT06243731

A Study of Maribavir in Adults With Kidney Failure Who Have a Cytomegalovirus (CMV) Infection After Transplantation

Retrospective Chart Review of Safety Outcomes Associated With Use of Maribavir in Patients With Post-transplant Refractory Cytomegalovirus (CMV) Infection and Comorbid Severe Chronic Kidney Disease (CKD) or Comorbid End-stage Renal Disease (ESRD), Including Patients on Peritoneal Dialysis or Hemodialysis

Sponsor

Takeda

Enrollment

10 participants

Start Date

Nov 3, 2025

Study Type

OBSERVATIONAL

Conditions

Kidney Disease Cytomegalovirus (CMV)Kidney Failure

Summary

The main aim of this study is to assess the safety of maribavir in adults with severe CKD or comorbid ESRD including participants on artificial filtering of the kidney (dialysis) or the blood (hemodialysis). In this study, already existing data will be collected from the participant's medical records. The study will only review data collected as part of the normal clinical routine and will not impact the standard medical care and treatment of participants.

Eligibility

Min Age: 18 Years

Plain Language Summary

Simplified for easier understanding

This study is looking at real-world data on how maribavir — an antiviral drug approved for treating cytomegalovirus (CMV) infections that do not respond to standard antivirals — works in patients who have had a transplant (organ or stem cell) AND also have severe kidney disease or kidney failure. **You may be eligible if...** - You are 18 or older - You have received a solid organ transplant (such as a kidney, liver, or heart) or a stem cell transplant - You have severe chronic kidney disease or kidney failure (including dialysis patients) - You developed a CMV infection after transplant that was resistant or refractory to standard antiviral drugs - You were treated with maribavir for this infection **You may NOT be eligible if...** - You did not have a transplant - You do not have severe kidney disease as defined in the study criteria - You were not treated with maribavir - Your records are not available for data collection Talk to your doctor to see if this trial is right for you.

This summary was AI-generated to explain the trial in plain language. It is not medical advice. Always discuss eligibility with your doctor before enrolling in a clinical trial.

Interested in this trial?

Get notified about updates and connect with the research team.

Interventions

OTHERNo Intervention

This is a non-interventional study.

Locations(25)

Hopital Erasme - PPDS

Anderlecht, Brussels Capital, Belgium

UZ Leuven - PPDS

Leuven, Vlaams Brabant, Belgium

North Estonia Medical Centre Foundation

Tallinn, Harju, Estonia

Tartu University Hospital

Tartu, Estonia

CHU de Brest - Hopital La Cavale Blanche

Brest, Finistere, France

CHU de Bordeaux - Hopital Pellegrin

Bordeaux, Gironde, France

CHU de Montpellier - Hopital Lapeyronie

Montpellier, Herault, France

CHU de Grenoble Alpes - Hopital Michallon

La Tronche, Isere, France

AP-HP - Hopital Henri Mondor

Créteil, Val-de-Marne, France

Universitatsklinikum Wurzburg

Würzburg, Bavaria, Germany

Universitatsklinikum Leipzig

Leipzig, Saxony, Germany

Azienda Ospedaliera Dei Colli - Ospedale Monaldi

Naples, Italy

Fondazione IRCCS Policlinico San Matteo

Pavia, Italy

Hospital Universitario de Bellvitge

L'Hospitalet de Llobregat, Barcelona, Spain

Hospital Universitario Cruces

Barakaldo, Vizcaya, Spain

Hospital Universitario Vall d'Hebron - PPDS

Barcelona, Spain

Hospital Clinic de Barcelona

Barcelona, Spain

C.H. Regional Reina Sofia - PPDS

Córdoba, Spain

Hospital Universitario Ramon y Cajal

Madrid, Spain

Hospital Regional Universitario de Malaga Hospital General

Málaga, Spain

Hospital Universitario Virgen del Rocio - PPDS

Seville, Spain

Dorset County Hospital

Dorchester, Dorset, United Kingdom

Queen Elizabeth Hospital Birmingham

Birmingham, United Kingdom

King's College Hospital

London, United Kingdom

Wrexham Maelor Hospital

Wrexham, United Kingdom

View Full Details on ClinicalTrials.gov

For the most up-to-date information, visit the official listing.

Visit

NCT06243731

Related Trials

A Study of Maribavir in Adults With Kidney Failure Who Have a Cytomegalovirus (CMV) Infection After Transplantation

Conditions

Summary

Eligibility

Plain Language Summary

Interventions

Locations(25)

Related Trials

A Study of Mezagitamab in Adults With Primary IgA Nephropathy Kidney Condition

Immune System Related Kidney Disease

Rutgers University Study of the Genetics of Kidney Disease

A High Protein Egg White Pudding for People With Kidney Failure (HiPE KF)

Shingrix in Renal Transplant Recipients